Optimization of in vivo tumor targeting in SCID mice with divalent forms of 741F8 Anti-c-erbB-2 single-chain Fv: effects of dose escalation and repeated i.v. administration
- DOI
- 10.1007/s002620050177
- Published
- 1995-06-01
- Container
- Cancer Immunology, Immunotherapy
- Publisher
- Springer Science and Business Media LLC
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1007/s002620050177,
title = {Optimization of in vivo tumor targeting in SCID mice with divalent forms of 741F8 Anti-c-erbB-2 single-chain Fv: effects of dose escalation and repeated i.v. administration},
author = {Gregory P. Adams and John E. McCartney and Ellen J. Wolf and Jamie Eisenberg and Mei-Sheng Tai and James S. Huston and Walter F. Stafford III and Michael A. Bookman and L. L. Houston and L. M. Weiner},
year = {1995},
journal = {Cancer Immunology, Immunotherapy},
doi = {10.1007/s002620050177},
url = {https://doi.org/10.1007/s002620050177}
}RIS
TY - JOUR TI - Optimization of in vivo tumor targeting in SCID mice with divalent forms of 741F8 Anti-c-erbB-2 single-chain Fv: effects of dose escalation and repeated i.v. administration AU - Gregory P. Adams AU - John E. McCartney AU - Ellen J. Wolf AU - Jamie Eisenberg AU - Mei-Sheng Tai AU - James S. Huston AU - Walter F. Stafford III AU - Michael A. Bookman AU - L. L. Houston AU - L. M. Weiner PY - 1995 JO - Cancer Immunology, Immunotherapy DO - 10.1007/s002620050177 UR - https://doi.org/10.1007/s002620050177 ER -
APA
Adams, G. P., McCartney, J. E., Wolf, E. J., Eisenberg, J., Tai, M., Huston, J. S., III, W. F. S., Bookman, M. A., Houston, L. L., & Weiner, L. M. (1995). Optimization of in vivo tumor targeting in SCID mice with divalent forms of 741F8 Anti-c-erbB-2 single-chain Fv: effects of dose escalation and repeated i.v. administration. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s002620050177
Source records
- crossref · retrieved 2026-09-25T01:36:40.958Z